Recent Billing Code Changes Wreaking Havoc for Radiation Oncologists, New Survey Finds

Why It Matters

The abrupt reimbursement decline threatens the financial viability of radiation‑oncology practices and jeopardizes patient access to essential cancer treatments. Immediate policy action is needed to prevent accelerated consolidation and care deserts.

Key Takeaways

• New CPT codes split radiation therapy into three complexity levels.
• Over 66% report payment cuts of 10% or more.
• Level 3 codes face frequent down‑coding and denial by payers.
• Independent clinics experience greatest financial strain and staff cuts.
• Legislative proposals aim to stabilize Medicare reimbursement for oncology.

Pulse Analysis

The 2026 CPT overhaul was intended to reflect technological advances in radiation oncology, but the rapid rollout left many providers scrambling to reinterpret billing rules. By segmenting procedures into simple, intermediate and complex tiers, the changes introduced new documentation requirements and eliminated the long‑standing CT‑guidance code 77014. Early adopters quickly discovered that Medicare’s fee‑schedule valuations lag behind the clinical reality, prompting a wave of unexpected revenue shortfalls across both freestanding and hospital‑based settings.

Financial pressure is already reshaping the specialty. The ASTRO survey indicates that more than two‑thirds of respondents face payment reductions of at least 10%, with a notable share reporting cuts up to 30%. Such declines have forced practices to lay off staff, reduce payroll, and, in some cases, shutter services altogether. The trend compounds a decade‑long erosion of radiation‑therapy reimbursement—over 25% on average—while operational costs continue to rise. As independent clinics bear the brunt, the market is seeing heightened consolidation, creating geographic “RT deserts” that limit timely access to curative cancer care.

Policymakers are now weighing legislative fixes. The Provider Reimbursement Stability Act of 2026 seeks to cap Medicare fee‑schedule cuts, while the Radiation Oncology Case Rate (ROCR) Value‑Based Payment Program Act of 2025 proposes a shift toward quality‑based payments rather than volume. If enacted, these measures could restore financial equilibrium, encourage investment in advanced equipment, and safeguard patient access. Stakeholders—including professional societies, payers, and advocacy groups—must collaborate to refine code definitions, streamline documentation, and ensure that reimbursement aligns with the true value of modern radiation oncology services.